TARS FY 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$451M+146.7% YoY

Gross Profit

$421M93.2% margin

Operating Income

-$71M-15.7% margin

Net Income

-$66M-14.7% margin

EPS (Diluted)

$-1.59

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$22M

Stock-Based Comp.

$42M

Balance Sheet

Total Assets

$562M

Total Liabilities

$219M

Stockholders' Equity

$343M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$451M	$183M	+146.7%
Gross Profit	$421M	$170M	+147.3%
Operating Income	-$71M	-$121M	+41.1%
Net Income	-$66M	-$116M	+42.5%